1-19 of 19
Adrian Wiestner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Anfal Alsadhan, Jonathan Chen, Erika M. Gaglione, Chingiz Underbayev, Pamela L. Tuma, Xin Tian, Lita A. Freeman, Sivasubramanian Baskar, Pia Nierman, Susan Soto, Andy Itsara, Inhye E. Ahn, Clare Sun, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, Adrian Wiestner
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3612–3621.
https://doi.org/10.1158/1078-0432.CCR-22-3217
Published: 15 September 2023
View article titled, CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Open the PDF for CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy in another window
Includes: Supplementary data
Journal Articles

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

Jennifer A. Woyach, Paolo Ghia, John C. Byrd, Inhye E. Ahn, Carol Moreno, Susan M. O'Brien, Daniel Jones, Leo W.K. Cheung, Elizabeth Chong, Kevin Kwei, James P. Dean, Danelle F. James, Adrian Wiestner
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3065–3073.
https://doi.org/10.1158/1078-0432.CCR-22-3887
Published: 15 August 2023
View article titled, B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
Open the PDF for B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy in another window
Includes: Supplementary data
Journal Articles

Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Maria Joao Baptista, Sivasubramanian Baskar, Erika M. Gaglione, Keyvan Keyvanfar, Inhye E. Ahn, Adrian Wiestner, Clare Sun
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4624–4633.
https://doi.org/10.1158/1078-0432.CCR-20-4894
Published: 15 August 2021
View article titled, Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Open the PDF for Select Antitumor Cytotoxic CD8<sup>+</sup> T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in another window
Includes: Supplementary data
Journal Articles

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib

Christian Brieghel, Kathrine Aarup, Mathias H. Torp, Michael A. Andersen, Christina W. Yde, Xin Tian, Adrian Wiestner, Inhye E. Ahn, Carsten U. Niemann
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4531–4538.
https://doi.org/10.1158/1078-0432.CCR-20-4890
Published: 15 August 2021
View article titled, Clinical Outcomes in Patients with Multi-Hit <em>TP53</em> Chronic Lymphocytic Leukemia Treated with Ibrutinib
Open the PDF for Clinical Outcomes in Patients with Multi-Hit <em>TP53</em> Chronic Lymphocytic Leukemia Treated with Ibrutinib in another window
Includes: Supplementary data
Journal Articles

SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma

Shashidhar S. Jatiani, Stephanie Christie, Violetta V. Leshchenko, Rinku Jain, Abhijeet Kapoor, Paola Bisignano, Clement Lee, H. Ümit Kaniskan, Donna Edwards, Fanye Meng, Alessandro Laganà, Youssef Youssef, Adrian Wiestner, Lapo Alinari, Jian Jin, Marta Filizola, Aneel K. Aggarwal, Samir Parekh
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4652–4663.
https://doi.org/10.1158/1078-0432.CCR-20-5039
Published: 15 August 2021
View article titled, SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma
Open the PDF for SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Anfal Alsadhan, Jean Cheung, Michael Gulrajani, Erika M. Gaglione, Pia Nierman, Ahmed Hamdy, Raquel Izumi, Elena Bibikova, Priti Patel, Clare Sun, Todd Covey, Sarah E.M. Herman, Adrian Wiestner
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12): 2800–2809.
https://doi.org/10.1158/1078-0432.CCR-19-3505
Published: 15 June 2020
View article titled, Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib
Open the PDF for Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib in another window
Includes: Supplementary data
Journal Articles

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model

Carsten U. Niemann, Helena I. Mora-Jensen, Eman L. Dadashian, Fanny Krantz, Todd Covey, Shih-Shih Chen, Nicholas Chiorazzi, Raquel Izumi, Roger Ulrich, Brian J. Lannutti, Adrian Wiestner, Sarah E.M. Herman
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5814–5823.
https://doi.org/10.1158/1078-0432.CCR-17-0650
Published: 01 October 2017
View article titled, Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model
Open the PDF for Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model in another window
Includes: Supplementary data
Journal Articles

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E.M. Herman, Arnau Montraveta, Carsten U. Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2831–2841.
https://doi.org/10.1158/1078-0432.CCR-16-0463
Published: 31 May 2017
View article titled, The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Open the PDF for The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia

Alba Matas-Céspedes, Anna Vidal-Crespo, Vanina Rodriguez, Neus Villamor, Julio Delgado, Eva Giné, Heleia Roca-Ho, Pablo Menéndez, Elías Campo, Armando López-Guillermo, Dolors Colomer, Gaël Roué, Adrian Wiestner, Paul W.H.I. Parren, Parul Doshi, Jeroen Lammerts van Bueren, Patricia Pérez-Galán
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (6): 1493–1505.
https://doi.org/10.1158/1078-0432.CCR-15-2095
Published: 14 March 2017
View article titled, The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
Open the PDF for The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Ibrutinib Inhibits VLA-4–Dependent Adhesion in CLL—Reply

Sarah E.M. Herman, Adrian Wiestner
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (13): 3412.
https://doi.org/10.1158/1078-0432.CCR-16-0605
Published: 30 June 2016
View article titled, Ibrutinib Inhibits VLA-4–Dependent Adhesion in CLL—Reply
Open the PDF for Ibrutinib Inhibits VLA-4–Dependent Adhesion in CLL—Reply in another window
Journal Articles

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study

Carsten U. Niemann, Sarah E.M. Herman, Irina Maric, Julio Gomez-Rodriguez, Angelique Biancotto, Betty Y. Chang, Sabrina Martyr, Maryalice Stetler-Stevenson, Constance M. Yuan, Katherine R. Calvo, Raul C. Braylan, Janet Valdez, Yuh Shan Lee, Deanna H. Wong, Jade Jones, Clare Sun, Gerald E. Marti, Mohammed Z.H. Farooqui, Adrian Wiestner
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1572–1582.
https://doi.org/10.1158/1078-0432.CCR-15-1965
Published: 31 March 2016
View article titled, Disruption of <em>in vivo</em> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
Open the PDF for Disruption of <em>in vivo</em> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study in another window
Includes: Supplementary data
Journal Articles

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy

Martin Skarzynski, Carsten U. Niemann, Yuh Shan Lee, Sabrina Martyr, Irina Maric, Dalia Salem, Maryalice Stetler-Stevenson, Gerald E. Marti, Katherine R. Calvo, Constance Yuan, Janet Valdez, Susan Soto, Mohammed Z.H. Farooqui, Sarah E.M. Herman, Adrian Wiestner
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1): 86–95.
https://doi.org/10.1158/1078-0432.CCR-15-1304
Published: 03 January 2016
View article titled, Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Open the PDF for Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy in another window
Includes: Supplementary data
Journal Articles

Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo

Sarah E.M. Herman, Rashida Z. Mustafa, Jade Jones, Deanna H. Wong, Mohammed Farooqui, Adrian Wiestner
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (20): 4642–4651.
https://doi.org/10.1158/1078-0432.CCR-15-0781
Published: 14 October 2015
View article titled, Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <em>In Vivo</em>
Open the PDF for Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics

Alba Navarro, Guillem Clot, Miriam Prieto, Cristina Royo, Maria Carmela Vegliante, Virginia Amador, Elena Hartmann, Itziar Salaverria, Sílvia Beà, Jose Ignacio Martín-Subero, Andreas Rosenwald, German Ott, Adrian Wiestner, Wyndham H. Wilson, Elías Campo, Luis Hernández
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (12): 3121–3129.
https://doi.org/10.1158/1078-0432.CCR-12-3077
Published: 13 June 2013
View article titled, microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics
Open the PDF for microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics in another window
Includes: Supplementary data
Journal Articles

ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress

Colby M. Chapman, Xiameng Sun, Mark Roschewski, Georg Aue, Mohamed Farooqui, Lawrence Stennett, Federica Gibellini, Diane Arthur, Patricia Pérez-Galán, Adrian Wiestner
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (7): 1979–1991.
https://doi.org/10.1158/1078-0432.CCR-11-2113
Published: 01 April 2012
View article titled, ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress
Open the PDF for ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress in another window
Includes: Supplementary data
Journal Articles

Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma

Marc A. Weniger, Edgar G. Rizzatti, Patricia Pérez-Galán, Delong Liu, Qiuyan Wang, Peter J. Munson, Nalini Raghavachari, Therese White, Megan M. Tweito, Kieron Dunleavy, Yihong Ye, Wyndham H. Wilson, Adrian Wiestner
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5101–5112.
https://doi.org/10.1158/1078-0432.CCR-10-3367
Published: 31 July 2011
View article titled, Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma
Open the PDF for Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia

Sivasubramanian Baskar, Ka Yin Kwong, Thomas Hofer, Jessica M. Levy, Michael G. Kennedy, Elinor Lee, Louis M. Staudt, Wyndham H. Wilson, Adrian Wiestner, Christoph Rader
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (2): 396–404.
https://doi.org/10.1158/1078-0432.CCR-07-1823
Published: 25 January 2008
View article titled, Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia
Open the PDF for Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia in another window
Journal Articles

Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines

Ana I. Robles, Mollie H. Wright, Bheru Gandhi, Steven S. Feis, Christin L. Hanigan, Adrian Wiestner, Lyuba Varticovski
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (21): 6547–6556.
https://doi.org/10.1158/1078-0432.CCR-06-1178
Published: 03 November 2006
View article titled, Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines
Open the PDF for Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines in another window
Includes: Supplementary data
Journal Articles

Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies

Matthias Grube, Katayoun Rezvani, Adrian Wiestner, Hiroshi Fujiwara, Giuseppe Sconocchia, Jan J. Melenhorst, Nancy Hensel, Gerald E. Marti, Larry W. Kwak, Wyndham Wilson, John A. Barrett
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (3): 1047–1056.
https://doi.org/10.1158/1078-0432.CCR-03-0075
Published: 10 February 2004
View article titled, Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies
Open the PDF for Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies in another window